{"entity":{"id":"nct07761533","kind":"trial","name":"PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS","aka":[],"tldr":"A phase 1/2 trial of PBSS1113 in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by Chaser Therapeutics, Inc., now recruiting.","summary":"PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS is a phase 1/2 interventional study registered as NCT07761533 by Chaser Therapeutics, Inc., with 29 participants planned, started 2025-09-08 and due to reach its primary completion in 2027-09. Interventions recorded: PBSS1113.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07761533","url":"https://clinicaltrials.gov/study/NCT07761533"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07761533","phase":"1/2","setting":"A Phase Ib/II, Open-Label, Dose-Escalation and Cohort Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PBSS1113 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","sponsor":"Chaser Therapeutics, Inc.","enrolled":29,"outcomes":[]},"route":"/trials/nct07761533/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}]}}